drugset / Trial / NCT00665600

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600

Phase 3 Completed 257 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the efficacy and safety of repeated dosing of Levalbuterol over 6 weeks of treatment in COPD.

Timeline

Start
2002-02
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 0.63 mg
Subject Levalbuterol Other / unclassified 1.25 mg
Subject Salbutamol Unknown 2.5 mg